Compare Abeona Therapeutics Inc (ABEO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs 10X Genomics Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while 10X Genomics Inc trades at $35.61 (market cap $4.80B). The key difference: 10X Genomics Inc is far larger — about 12.9× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | TXG | |
|---|---|---|
Market Cap | $373.32M | $4.80B |
Sector | Health | Health |
52-Week High | $7.23 | $40.00 |
52-Week Low | $4.17 | $11.34 |
Enterprise Value | $228.22M | $4.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TXG trades at $37.83, down 3.02% today, with a bullish technical setup despite recent weakness. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining strong 69.6% gross margins. Recent collaborations with Cleveland Clinic and the Proteintech acquisition enhance its multiomics capabilities. Technical indicators show strong momentum with the price above key moving averages, though RSI levels suggest potential overbought conditions near-term.
The outlook remains cautiously optimistic as TXG progresses toward profitability, with analyst consensus at $31.00 representing 18% downside risk. Key opportunities include expanding diagnostic applications and platform adoption, while risks center on continued losses, high valuation multiples, and competitive pressure in life sciences technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
